[ad_1]
Tests have revealed the ability to generate immunity in both young and elderly adults. Risk groups will be the first to be vaccinated with licenses for emergency cases, reveals the British newspaper Independent
The vaccine being developed by the University of Oxford could be validated and authorized before the end of the year, the English newspaper Independent reported today.
According to the same report, the data tested so far reveals that this possible vaccine generates similar immunities in young and old, according to information from AstraZeneca, a pharmaceutical company involved in the study and tests.
Immunogenicity tests, the ability of a substance to trigger an immune response in the body, performed on a group of older study participants revealed that the vaccine activates protective antibodies and T cells among the elderly, one of the oldest age groups. risk with respect to Covid-19.
“It is encouraging to see that immunogenicity responses were similar between older and younger adults, and that reactogenicity (adverse or secondary reaction) was lower among older adults, where the severity of disease 19 is higher,” said one . AstraZeneca spokesperson for Reuters news agency.
“The results [mais recentes do estudo] reinforce the evidence for the safety and immunogenicity of AZD1222, “the spokesperson added, referring to the technical name of the vaccine tested at Oxford.
However, says The Independent, despite these motivating results and the fact that older people can develop immunity from the vaccine, this does not guarantee that the vaccine is already in a state of development that guarantees its safety and effectiveness. In other words, this risk group needs to verify further analysis.
The Oxford vaccine, to be produced by AstraZeneca, is among the most advanced candidates, all of which are still in development, namely those from Pfizer and Moderna laboratories.
However, Adrian Hill, the lead researcher for the Oxford program, said that doctors and high-risk patients could receive doses of AZD1222 even before the end of 2020. “The first licenses will be for emergency use, they will not have widespread approval. “he told several members and alumni of Magdalen College, Oxford, one of the university’s prestigious colleges. According to Hill, regulators” will want to see more data on safety and efficacy before granting a license to vaccinate everyone. “
Oxford University and AstraZeneca are conducting tests at nine sites in Britain, involving 10,000 volunteers. Other tests are underway in Brazil, South Africa, India and the United States.
[ad_2]
